Recursion Doses First Patient in Phase 1 MALT1 Inhibitor Study
Recursion Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial, EXCELERIZE, for REC-3565, a potential best-in-class...
Jon Napitupulu
NKGen Biotech Unveils Promising Troculeucel Alzheimer’s Trial Data at AD/PD 2025
NKGen Biotech announced updated Phase 1 clinical trial data for troculeucel, an NK cell therapy for moderate Alzheimer’s disease....
ALX Oncology Gets FDA Clearance for Novel EGFR-Targeted ADC ALX2004
ALX Oncology received FDA clearance for its Investigational New Drug (IND) application for ALX2004, an antibody-drug conjugate (ADC) designed...
Teva’s Ajovy® FDA Filing Accepted for Pediatric Migraine Prevention
Teva Pharmaceuticals has submitted a supplemental Biologics License Application to the FDA for AJOVY (fremanezumab-vfrm) to prevent episodic migraines...
Reunion Neuroscience at ADAA 2025: Re104 for Adjustment Disorder
Reunion Neuroscience presented the design of its REKINDLE Phase 2 clinical trial, which will evaluate RE104 for treating adjustment...
Briumvi’s Impact Highlighted in Medical Journals
TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...
Rhythm’s Obesity Drug Shows -19.8% Placebo-Adjusted BMI Reduction in Phase 3
Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The...
IBIO-600 Primate Data Shows Extended Half-Life and Muscle Growth
iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting...
TR1X Awarded $8M Grant for TRX103 GvHD Trial
Tr1X, a clinical-stage biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to...
Son-1010 Shows Strong Safety in Ovarian Cancer Treatment
Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...